Olsutamig

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A bispecific antibody that targets both the tumor-associated antigen (TAA) human prostate-specific membrane antigen (PSMA) and the CD3 antigen found on T-lymphocytes, with potential immunostimulatory and antineoplastic activities. Upon administration,,olsutamig binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and PSMA found on PSMA-expressing tumor cells. This activates and redirects CTLs to PSMA-expressing tumor cells, which results in the CTL-mediated cell death of PSMA-expressing tumor cells. PSMA is overexpressed on the surface of metastatic and hormone-refractory prostate cancer cells.

**Synonyms:** - Anti-PSMA/CD3 Bispecific Antibody REGN4336 - OLSUTAMIG - PSMA X CD3 Bispecific Antibody REGN4336 - REGN 4336 - REGN-4336 - REGN4336